别名 Iboctadekin、IFN-gamma-inducing factor、IGIF + [12] |
简介 Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532, PubMed:37993714). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744). |
靶点 |
作用机制 IL-18抑制剂 |
在研机构 |
原研机构 |
在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 IL-18抑制剂 [+1] |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-02-13 |
申办/合作机构 |
开始日期2024-12-18 |
申办/合作机构 |
开始日期2024-09-23 |
申办/合作机构 |